Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Apr;16(2):89-92.
doi: 10.3132/pcrj.2007.00014.

The use of a modification of the Patient Enablement Instrument in asthma

John Haughney  1 , Philip Cotton, Jan-Paul Rosen, Jan-Paul Rosen, Ken Morrison, David Price
Affiliations
Randomized Controlled Trial

The use of a modification of the Patient Enablement Instrument in asthma

John Haughney et al. Prim Care Respir J. 2007 Apr.

Abstract

Aim: To ascertain if the Patient Enablement Instrument (PEI) could be adapted for use in asthma management, and to use it to evaluate "enablement" in patients with asthma randomised to either a fixed or adjustable medication dosing regime.

Methods: The original Patient Enablement Instrument was modified by making a minor change to the opening statement. 228 adults with asthma from 72 UK general practices were recruited to the study. The internal and external consistencies of the modified PEI were assessed. Individual scores were compared across treatment groups.

Results: The modified PEI had high internal consistency. There was a significant correlation between modified PEI total score and change in Mini Asthma Quality of Life Questionnaire. A significantly greater proportion of patients using adjustable medication dosing had a clinically relevant treatment benefit.

Conclusions: The Patient Enablement Instrument can be used to measure "enablement" in asthma.

PubMed Disclaimer

Conflict of interest statement

John Haughney has received fees from AstraZeneca, Boehringer Ingelheim and Merck Sharp & Dohme for speaking at meetings, and from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Novartis and Schering Plough for consulting.

Philip Cotton has spoken at meetings for AstraZeneca but has not received personal fees for doing so.

Jan-Paul Rosen and Ken Morrison are full time employees of AstraZeneca UK Ltd.

David Price has no shares in pharmaceutical companies. He has received speaker's honoraria for speaking at sponsored meetings from the following companies marketing respiratory products: 3M, Altana, AstraZeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering Plough. He has received honoraria for advisory panels from: 3M, Altana, AstraZeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer and Schering Plough. He or his research team have received funding for research projects from: 3M, Altana, AstraZeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering Plough and Viatris.

Publication types